“The Sprague Dawley rat and cynomolgus monkey were selected as the main rodent and non-rodent toxicology species as romosozumab binds to human, rat, and cynomolgus monkey sclerostin with similar affinity and is pharmacologically active in these species.”
Binds human, rat and cynomolgus sclerostin with similar affinity and is pharmacologically active in both species
“The Sprague Dawley rat and cynomolgus monkey were selected as the main rodent and non-rodent toxicology species as romosozumab binds to human, rat, and cynomolgus monkey sclerostin with similar affinity and is pharmacologically active in these species.”
No surrogate in toxicology; the clinical antibody was tested in rats and monkeys (rodent versions r13c7/m13c7 used in pharmacology/PK)
“In some studies, rodent versions of the humanized antibody AMG785 (rat 13c7 (r13c7) and mouse 13c7 (m13c7)) were used because AMG785 causes anti-drug antibody (ADA) formation in those species.”
✓ VerifiedFDA multi-discipline review, p. 561Source ↗